Vice Chair of Treasury Dept’s New Racial Equity Committee Alexandria Ocasio-Cortez Outlines Plans for Defunding PoliceOctober 5, 2022
Small Cancer Drug Trial Sees Tumors Disappear In 100 Percent of patients
We all know we are living in a dangerous time. War is all around us and death always follows the guilty and the innocent and shows no partiality. Getting or hearing good news is always a feeling of fresh air. This is one of those times. There has been a major breakthrough in cancer treatment. Even though the treatment is for just one type of cancer this opens the door to developing other Cancer treatments.
Researchers are excited about this outcome, and they hope it will translate into new treatments for other types of cancer. Colorectal cancer researchers on Sunday welcomed the results of a small-scale study of the drug as a breakthrough that may also lead to new treatments for other tumors. Researchers within the colorectal cancer sphere are hailing a small drug study Sunday as a groundbreaking improvement that will lead to new treatments for other cancers as well.
In what appears to be a highly promising breakthrough in rectal cancer care, a small drug trial conducted in the United States found every patient treated in the experiment had his or her cancer go into successful remission. Of 12 patients with rectal cancer treated with the drug, called Dostarlimab, each saw his or her tumor go away, according to results from the trial, published on June 5 in The New England Journal of Medicine. In one trial, 18 patients took the experimental therapy for about six months, according to The New York Times, and at the end, each saw his or her tumors disappear.
In what appears to be a very promising breakthrough for the treatment of rectal cancer, a small drug trial conducted in the US found every patient treated in the experiment had their cancer successfully go into remission.
The medication given, called dostarlimab and sold under the brand name Jemperli, is an immunotherapy drug used in the treatment of endometrial cancer, but this was the first clinical investigation of whether it was also effective against rectal cancer tumors.
The early results reported so far suggest it is surprisingly effective, with the research team saying the successful cancer remission seen in every trial patient may be unprecedented for a cancer drug intervention.
“I believe this is the first time this has happened in the history of cancer,” medical oncologist Luis Diaz Jr. from Memorial Sloan Kettering Cancer Center (MSK), the senior author of a new paper reporting the results, told The New York Times. “sciencealert.com“
David Ryan, chief of Clinical Oncology at Massachusetts General Hospital, said that these results are groundbreaking for patients with malignancy who have MMRd. For David Ryan, even a small study with one drug reinforced the importance for cancer patients to understand the status of mismatch repair. David Ryan and Cercek, separately, said the findings raised the prospect that anyone who has maladjustment repair deficiencies in other tumors, like those in the pancreas, stomach, or bladder, might be effectively treated with the same drugs that are used to cure A.D.
The findings indicate a promising alternative for treating rectal cancer, which can often leave patients with life-altering effects. Six months after experimental treatments, tumors disappeared in all 14 patients diagnosed with early-stage rectal cancer who had completed the trial at the time of its publication.
The results were so successful that none of the 14 patients who completed the small-scale drug study needed scheduled subsequent chemotherapy-radiation or surgical treatments, and there were no serious complications with dostarlimab given intravenously. The results were so successful that none of the 14 patients who completed A small drug study needed the planned follow-up treatment of chemo-radiation or surgical procedures, nor did any have any significant complications from A small drug study.
Early results reported so far indicate that it is strikingly effective, and the study team says that the successful remission from cancer seen in each patient on trial could be unprecedented for an intervention drug for a form of cancer. However, the trial with just 12 patients is extremely small, and therefore larger studies on using a new drug are needed to confirm its effectiveness and safety for use with patients with cancer.
When we have data from around 30 patients, we will have a complete picture of how safe and effective a given medication is for patients with rectal cancer, though far larger studies are still needed with larger groups of patients. Even six months after treatment, all 12 patients showed no evidence of cancer on the rectum through NMR imaging, endoscopic assessment, digitized rectal exams, or biopsies.
None has received chemotherapy since then or had surgery for a recurrence, said researchers at Memorial Sloan Kettering Cancer Center. In each case, rectal cancer disappeared following immunotherapy–without requiring standard treatments such as radiation, surgery, or chemotherapy–and cancer has not returned in any of the patients, who have been free of the disease for as long as two years.
God Bless the United States, God Bless the Veterans
If you enjoyed this article, then please REPOST or SHARE with others; encourage them to follow Our Nation Stands